3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
11
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
3
HER2-positive Breast Cancer
3
Colorectal Neoplasms
3
Advanced Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
HER2 Overexpression
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
Trastuzumab
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
romidepsin
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
larotrectinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
erdafitinib
1
entinostat
1
durvalumab
1
diazepinomicin
1
defactinib
1
dabrafenib
1
copanlisib
1
clevudine
1
cediranib
1
carboxyamido-triazole
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
trastuzumab deruxtecan
×
Breast
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled